[4.3.1]Bicyclic FKBP Ligands Inhibit Legionella Pneumophila Infection by LpMip-Dependent and LpMip-Independent Mechanisms

Chembiochem. 2023 Nov 2;24(21):e202300442. doi: 10.1002/cbic.202300442. Epub 2023 Sep 8.

Abstract

Legionella pneumophila is the causative agent of Legionnaires' disease, a serious form of pneumonia. Its macrophage infectivity potentiator (Mip), a member of a highly conserved family of FK506-binding proteins (FKBPs), plays a major role in the proliferation of the gram-negative bacterium in host organisms. In this work, we test our library of >1000 FKBP-focused ligands for inhibition of LpMip. The [4.3.1]-bicyclic sulfonamide turned out as a highly preferred scaffold and provided the most potent LpMip inhibitors known so far. Selected compounds were non-toxic to human cells, displayed antibacterial activity and block bacterial proliferation in cellular infection-assays as well as infectivity in human lung tissue explants. The results confirm [4.3.1]-bicyclic sulfonamides as anti-legionellal agents, although their anti-infective properties cannot be explained by inhibition of LpMip alone.

Keywords: Antiinfective; Inhibitors; Isomerases; Legionella pneumophila; Medicinal chemistry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Proteins / metabolism
  • Humans
  • Legionella pneumophila* / metabolism
  • Legionella* / metabolism
  • Legionnaires' Disease* / drug therapy
  • Legionnaires' Disease* / microbiology
  • Peptidylprolyl Isomerase / chemistry
  • Peptidylprolyl Isomerase / metabolism
  • Tacrolimus Binding Proteins

Substances

  • Tacrolimus Binding Proteins
  • Peptidylprolyl Isomerase
  • Bacterial Proteins